tavalisse
Generic: fostamatinib disodium hexahydrate·Code: R788
tavalisse: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| RIGEL PHARMACEUTICALS INC (RIGL) | Approved |
FDA Decisions
Approval1 INDICATIONS AND USAGE TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.(RIGL)
Frequently asked questions
Who is developing tavalisse?
tavalisse is being developed by RIGEL PHARMACEUTICALS INC.
What is tavalisse's latest FDA decision?
The most recent tracked FDA decision for tavalisse is Approval for 1 INDICATIONS AND USAGE TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment., dated April 17, 2018.
Get deeper analysis on tavalisse
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis